On April 7, 2022 Ultivue, an industry leader in multiplexing tools for tissue biomarker analysis, and Paige, the global leader in AI-based diagnostic software in pathology, reported a partnership to collaborate on the co-development and co-marketing of AI-powered spatial immunophenotype capabilities to pharmaceutical and research customers (Press release, Ultivue, APR 7, 2022, View Source [SID1234611609]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Collaborative efforts will initially focus on the development of AI to enable improved understanding of the tumor microenvironment and support the interpretation of Ultivue’s novel multiplex immunofluorescence (mIF) immuno-oncology biomarker panels.

The Paige portfolio includes the Paige Platform, a comprehensive imaging solution composed of the FDA-cleared and CE-marked FullFocus, an intuitive and responsive viewer for pathology scans that supports primary diagnosis together with a data management solution for storage of pathology scans. The fast, zero-footprint, scanner-agnostic viewer, storage capabilities and AI-based diagnostic software help pathologists review cases and support their overall workflow.

Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique platform agnostic solutions for use in both mIF imaging and spatial phenomics. Its proprietary InSituPlex technology, designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in precious tissue samples combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology.

"This collaboration with Paige is an exciting milestone for Ultivue as we consider the evolving impact of AI and deep learning tools on histopathological images in clinical settings," said Jacques Corriveau, CEO, Ultivue. "Importantly, our aligned goals are to facilitate the decentralization and democratization of the generation and analysis of complex spatial data."

"The combination of Ultivue’s robust biomarker detection capabilities and Paige’s AI-enabled computational pathology technology allows us to deliver new products that will elevate how immuno-oncology research is done today," said David Klimstra, M.D., Founder and Chief Medical Officer at Paige. "By uniting two platform-agnostic technologies, we are well-positioned to enable broad adoption of our AI-powered biomarker imaging solutions."

On April 7, 2022 InterVenn Biosciences, an innovator in glycoproteomics, reported that it will share new data from glycoproteomic analysis on its perspectIV platform in poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 taking place in New Orleans, April 8–13, 2022 (Press release, InterVenn Biosciences, APR 7, 2022, View Source [SID1234611608]). In addition, world-renowned Stanford professor Carolyn Bertozzi, Ph.D., an InterVenn co-founder, and Klaus Lindpaintner, MD, MPH, InterVenn Distinguished Scientist, will share their insights during the InterVenn Exhibitor Spotlight Theater on April 10 on how glycoproteomics can advance translational research with the aim of helping to improve outcomes for cancer patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The glycoproteome represents a new dimension of biology and a previously untapped source of profound new insights into disease mechanisms and potentially powerful new diagnostic tools," said Aldo Carrascoso, CEO of InterVenn Biosciences. "We look forward to sharing our glycoproteomic insights at AACR (Free AACR Whitepaper) this year, including how glycoproteomics is accelerating the shift from disease management to the new realm of preventive care and life management."

InterVenn offers a glycoproteomic service that provides access to the glycoproteome at scale and cost-effectively to a wide range of healthcare companies and laboratories. The service is based on InterVenn’s perspectIV platform, which is a novel, high-throughput analytical tool designed to interrogate the blood-based glycoproteome, extract new insights, and develop diagnostic solutions.

The InterVenn approach addresses many of the common challenges associated with liquid biopsy analysis by industrializing the process of glycoproteomics-based blood testing at high accuracy and rapid turn-around time. It requires a significantly lower sample volume than most other analytical platforms. Also, unlike these other approaches, the perspectIV platform is not dependent on material shed by the tumor, allowing the detection of small, early stage, curable tumors that are commonly missed by other analytical methods.

InterVenn Presentations and Event at AACR (Free AACR Whitepaper)

InterVenn will present two scientific posters highlighting new data that demonstrate how glycoproteomics is advancing translational research in oncology.

Title: "Glycoproteomics-based liquid biopsy informs optimal checkpoint-inhibitor drug choice"
Date/Time: April 11, 9 a.m.−12:30 p.m.
Presenter: Klaus Lindpaintner, MD, MPH; Distinguished Scientist, InterVenn
Location: Section 31

Title: "Peripheral blood glycoproteomic biomarkers as a powerful new tool for the detection of nasopharyngeal carcinoma"
Date/Time: April 12, 9 a.m.−12:30 p.m.
Presenter: Klaus Lindpaintner, MD, MPH; Distinguished Scientist, InterVenn
Location: Section 32

About the Glycoproteome

The glycoproteome represents the entirety of all glycosylated proteins in an organism. Glycosylation is the attachment of different sugar molecules (glycans) to proteins, a process that affects the majority of proteins, resulting in an often very large number of glyco-isoforms of one and the same protein. The extensive and complex family of glycans thus represents, beyond nucleic acids and proteins, an additional class of important information-carrying biomolecules, dubbed the "third alphabet of biology."

Glycosylation is of profound biological importance as the addition of different glycans fundamentally affects structure and function of proteins, with significant impact on the crucial roles they play in all biological processes, including immune response and cell signaling, and, therefore, in health and disease − notably in cancer. Due to the varied and essential roles glycoproteins play in physiological functions, and because of the dynamic and integrative nature glycoproteomic biomarkers present, they have the potential to be clinically highly relevant for real-time decision-making with direct impact on patient care. Glycoproteomic analysis enables novel biological insights beyond what genome sequence analysis can provide.

On April 7, 2022 BostonGene reported that six abstracts were selected for poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, which will be held from April 8 – 13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. In addition, BostonGene will exhibit at booth #3641 (Press release, BostonGene, APR 7, 2022, View Source [SID1234611607]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations describe BostonGene’s development of novel analytical tools and demonstrate results of work conducted with multiple leading cancer centers in the United States. The findings highlight the application of BostonGene’s cutting-edge technologies to improve the diagnosis and treatment of cancer patients.

"We look forward to showcasing our research at the AACR (Free AACR Whitepaper) Annual Meeting. Our findings underscore the clinical utility of BostonGene‘s deep molecular and immune profiling and analytics to advance precision medicine for cancer patients," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Details of the poster presentations are below:

Title: 1216 / 12 – Combinatory technologies for single sample gene expression projection onto a cohort sequenced with a different technology for personalized clinical decision-making
Session: PO.BCS01.01. New Algorithms and Tools for Data Analysis
Date and Time: Monday, April 11 | 9:00 AM – 12:30 PM
Location: Exhibit Halls D-H, Poster Section 29
Presenter: Krystle Nomie, PhD, BostonGene

Title: 1227 / 23 – Molecular-based tumor grade predictor for breast cancer, clear cell renal cell carcinoma, and lung adenocarcinoma
Session: PO.BCS01.01. New Algorithms and Tools for Data Analysis
Date and Time: Monday, April 11 | 9:00 AM – 12:30 PM
Location: Exhibit Halls D-H, Poster Section 29
Presenter: Alexander Bagaev, PhD, BostonGene

Title: 2061 / 19 – Deep immune profiling by mass cytometry revealed an association between the state of immune system before treatment and response to checkpoint inhibitor therapy in clear cell renal cell carcinoma
Session: PO.IM02.13 – Immune Response to Therapies 1
Date and Time: Monday, April 11 | 1:30 PM – 5:00 PM
Location: Exhibit Halls D-H, Poster Section 37
Presenter: Michael Goldberg, PhD, BostonGene

Research conducted with Stanford University School of Medicine and Washington University School of Medicine

E-Poster presentations

E-Posters will be available starting at 1:00 PM CST on Friday, April 8, 2022, the first day of the AACR (Free AACR Whitepaper) Annual Meeting. All e-posters will be made available for browsing on the AACR (Free AACR Whitepaper) Annual Meeting website on this date.

Title: 3823 / 23 – Viral transcript and tumor immune microenvironment-based transcriptomic profiling of HPV-associated head and neck cancer identifies subtypes associated with prognosis
Session: PO.TB06.04 – Gene Expression and the Microenvironment
Presenter: Daria Kiriy, BostonGene

Research conducted with Massachusetts General Hospital, University of Kentucky, Vanderbilt University Medical Center, University of Pittsburgh Cancer Institute, Washington University School of Medicine, Harvard Medical School

Title: 6151 – Tumor microenvironment heterogeneity identifies potential biomarkers of response in ER-positive breast cancers treated with palbociclib
Session: OPO.TB06.01. Tumor Microenvironment
Presenter: Maria Bruttan, BostonGene

Research conducted with Cedars-Sinai Medical Center, Stanford University School of Medicine, and Washington University School of Medicine

Title: 5172 – B cell content in the tumor microenvironment is associated with improved survival in stage II lung adenocarcinoma
Session: OPO.CL11.01 – Biomarkers
Presenter: Ivan Valiev, MSc, BostonGene

Research conducted with Massachusetts General Hospital

Additionally, the abstracts will be published in an online-only Proceedings supplement to the AACR (Free AACR Whitepaper) journal Cancer Research after the completion of the AACR (Free AACR Whitepaper) Annual Meeting.

On April 7, 2022 Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, reported that company management will present at the upcoming 21st Annual Needham Virtual Healthcare Conference on April 12, 2022 at 1:30 p.m. EDT (Press release, Gamida Cell, APR 7, 2022, View Source [SID1234611606]). Management will discuss 2022 catalysts and potential milestones including executing its U.S. commercial strategy for the launch of the first allogenic stem cell therapy upon U.S. Food and Drug Administration approval, accelerating the development of its first-in-class NAM-enabled natural killer (NK) cell therapy, GDA-201, as a new approach for patients with follicular and diffuse large B-cell lymphomas, and expansion of its NAM-enabled cell therapy pipeline with multiple next-generation, genetically engineered NK cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additionally, Julian Adams, Ph.D., chief executive officer of Gamida Cell, will participate in a live panel discussion titled "Company Perspectives: Companies Discussing Key Features and Differentiators in the NK Cellular Therapeutics Space," on April 14, 2022 at 11:00 a.m. EDT.

The webcast of the presentation will be available on the "Investors & Media" section of Gamida Cell’s website at www.gamida-cell.com, and will be available for at least 14 days following the event.

About NAM Technology

Our NAM-enabling technology is designed to enhance the number and functionality of targeted cells, enabling us to pursue a curative approach that moves beyond what is possible with existing therapies. Leveraging the unique properties of NAM, we are able to expand and metabolically modulate multiple cell types — including stem cells and natural killer cells — with appropriate growth factors to maintain the cells’ active phenotype and enhance potency. This allows us to administer a therapeutic dose of cells that may help cancer patients live longer better lives.

On April 7, 2022 Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, reported that it will be presenting a poster at the 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Vizgen, APR 7, 2022, View Source [SID1234611605]). Conducted with Massachusetts General Hospital (MGH), the poster will report how a spatially resolved map of colorectal cancer can best identify novel spatial relationships between cancer cells and the microenvironment. An e-poster will be made available beginning on Friday, April 8 at 1 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:
Title: A single-cell spatially resolved map of colorectal cancer identifies novel spatial relationships between cancer cells and the microenvironment
Presenting Author: Colles Price, MS, Ph.D., Senior Research Scientist – Oncology Lead, Vizgen
Abstract #: 2030
Session Title: Spatial Proteomics and Transcriptomics
Session Date and Time: April 11, 2022, 1:30 p.m. – 5:00 p.m.
Location: New Orleans Convention Center, Poster Section 34, Poster Board #8

In addition to the company’s poster presentation at AACR (Free AACR Whitepaper), Vizgen showcased preliminary data performing in situ single-cell transcriptomic imaging in formalin-fixed paraffin-embedded (FFPE) tissue sections with its MERSCOPE platform, powered by multiplexed error robust in situ hybridization (MERFISH) technology. FFPE tissues are the most widely used clinical sample types in histology and molecular diagnosis. However, due to RNA degradation and protein crosslinking, FFPE samples are often not compatible with single-cell transcriptomic analysis. Dr. Jiang He, Scientific Co-founder and Senior Director of Scientific Affairs at Vizgen, recently presented a webinar demonstrating MERFISH imaging in more than 15 FFPE sample types from mouse and human, including archival clinical samples. The webinar can be viewed here.

"We are buoyed by the tremendous adoption of MERSCOPE since the platform’s U.S. launch in the beginning of the year as customers realize the vast benefits of a high multiplexing, high resolution in situ platform to combine single-cell and spatial genomics," said Terry Lo, President and CEO of Vizgen. "Spatial context, as underscored by the presentation at AACR (Free AACR Whitepaper), is critical to advancing therapies for immunologically distinct colon cancer types and the high resolution and sensitivity of MERSCOPE data has the potential to aid researchers in uncovering new findings in the tumor microenvironment."